Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes

Eur J Cancer. 2016 Mar:56:162-171. doi: 10.1016/j.ejca.2015.12.022. Epub 2016 Feb 12.

Abstract

Nab-paclitaxel is a novel therapeutic agent, which was approved in combination with carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC) regardless of histologic subtype in the United States of America by the Food and Drug Administration in 2012 and by the European Commission in 2015. This approval was based on the results of a phase III clinical trial showing superior response rates compared with solvent-based paclitaxel in combination with carboplatin. This review will focus on the early development and clinical data to date supporting the use of nab-paclitaxel in advanced NSCLC. The clinical question central to this review is whether nab-paclitaxel has a place in the current therapeutic landscape of advanced NSCLC.

Keywords: Carboplatin; Elderly; Nab-paclitaxel; Neuropathy; Non-small cell lung cancer (NSCLC); Squamous cell histology.

Publication types

  • Review

MeSH terms

  • Albumins / adverse effects
  • Albumins / therapeutic use*
  • Animals
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carboplatin / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Chemistry, Pharmaceutical
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / mortality
  • Lung Neoplasms / pathology
  • Paclitaxel / adverse effects
  • Paclitaxel / therapeutic use*
  • Patient Selection
  • Risk Factors
  • Treatment Outcome

Substances

  • 130-nm albumin-bound paclitaxel
  • Albumins
  • Antineoplastic Agents
  • Carboplatin
  • Paclitaxel